急性心肌梗死预后生化标志物的研究进展  

Research Advances in Prognostic Biomarkers of Acute Myocardial Infarction

作　　者：代佩灵[1] 张翠丽[1] 富路[1] 

机构地区：[1]哈尔滨医科大学附属第一医院心内科,哈尔滨150001

出　　处：《医学综述》2012年第17期2746-2748,共3页Medical Recapitulate

摘　　要：急性心肌梗死后往往伴随许多并发症,生化标志物能对由泵衰竭、炎性反应和不稳定动脉粥样硬化斑块进展引起的急性心肌梗死后并发症(如心力衰竭、心肌梗死后综合征、经皮冠状动脉介入治疗或溶栓后再梗死等)进行有效的预测和监测,为急性心肌梗死的早期诊断、积极治疗、病情监测以及治疗评估提供有力的依据。现主要针对B型脑钠肽、ST2、肾上腺髓质素、和肽素、内皮素1、肌酸激酶同工酶、心肌肌钙蛋白、心肌型脂肪酸结合蛋白、可溶性CD40L、生长分化因子15、C反应蛋白等预后标志物进行简要介绍。Many complications may occur following acute myocardial infarction （AMI）. Biomarkers can make effective prediction and monitoring about post AMI complications caused by pump failure, inflammation or unstable athemsclerosis plaque progression, such as heart failure, postmyocardial infarction syndrome, per- cutaneous coronary intervention or post thrombolytic reinfarction, etc.. These biomarkers can be used as early diagnosis, active treatment, condition monitoring and treatment assessment after AMI. Here is to give a brief introduction about prognostic biomarkem of acute myocardial infarction,including B-type natriuretic peptide, ST2, adrenomedullin, copeptin, endothelin-1, creatine kinase isoenzyme, cardiac troponin, heart-type fatty acid binding protein, soluble CD40L, growth differentiation factor-15, C-reactive protein and so on.

关 键 词：急性心肌梗死 生化标志物 预后 诊断 

分 类 号：R541.4[医药卫生—心血管疾病]